1. What Is the Glaucoma Device Market?
The Glaucoma Device Market covers micro-invasive glaucoma surgery implants, tube shunt drainage implants, selective laser trabeculoplasty systems, and cyclodestructive laser platforms lowering intraocular pressure by enhancing aqueous outflow in open-angle, angle-closure, and secondary glaucoma. Ophthalmologists and glaucoma surgeons at glaucoma specialty programs implant Glaucoma Device products during standalone procedures or combined with cataract surgery when pressure reduction and lens extraction are needed concurrently. The market spans trabecular bypass MIGS stents, subconjunctival filtration MIGS devices, suprachoroidal aqueous drainage systems, tube shunts for refractory glaucoma, and laser systems for selective trabeculoplasty and cyclophotocoagulation procedures. MIGS devices are transforming the intervention spectrum between topical drug therapy and conventional filtration surgery by offering a less invasive surgical option suitable for mild-to-moderate glaucoma managed as part of cataract surgery.
2. Glaucoma Device Market Size & Forecast
3. Emerging Technologies
- MIGS trabecular bypass stents implanted through the anterior chamber angle are reducing aqueous outflow resistance at the trabecular meshwork without conjunctival dissection, enabling pressure reduction through the same small incision used for concurrent cataract surgery. The stents achieve meaningful intraocular pressure reduction and medication elimination in randomized trials, and their minimal-risk profile has made trabecular bypass MIGS the fastest-adopted surgical glaucoma intervention.
- Subconjunctival filtration MIGS implants establishing ab-interno drainage pathways beneath the conjunctiva are extending bleb-based filtration to mild-to-moderate glaucoma patients outside of conventional trabeculectomy referral criteria. These devices reduce tissue manipulation compared to conventional filtration surgery while creating functional conjunctival drainage that lowers intraocular pressure in both combined cataract-glaucoma and standalone surgical settings.
- Selective laser trabeculoplasty applies low-energy nanosecond pulses to trabecular pigment cells, stimulating outflow facility without thermal coagulation and preserving a tissue substrate safe for repeat treatment. The LiGHT randomized trial established this procedure as a non-inferior first-line alternative to topical medication in newly diagnosed open-angle glaucoma patients.
- Suprachoroidal space drainage devices implanting ab-interno microstents to create an outflow pathway into the suprachoroidal space are augmenting uveoscleral outflow as an additional drainage route supplementing trabecular and subconjunctival pathways. These devices provide pressure reduction through a distinct anatomical compartment and are being evaluated in standalone and combined cataract procedures to characterize their durability and safety in varied glaucoma severity populations.
Such innovations are driving change across adjacent industries too. Discover more in our Cataract Surgery Market.
4. Key Market Opportunity
Within the Glaucoma Device Market, the most immediate commercial opportunity lies in MIGS adoption at cataract surgery programs where surgeons performing high annual phacoemulsification volumes can add trabecular bypass stent implantation to eligible mild-to-moderate glaucoma patients simultaneously, generating incremental glaucoma procedure revenue from the existing cataract patient population without requiring separate surgical scheduling. Subconjunctival MIGS representing a less invasive alternative to trabeculectomy is growing as a standalone treatment option at glaucoma specialty programs, where surgeons can offer a bleb-based filtration option earlier in the disease course than conventional practice guidelines for incisional surgery referral. Selective laser trabeculoplasty as first-line therapy represents a practice-level economic opportunity at glaucoma clinics where laser systems generate per-procedure revenue from a therapy that the LiGHT trial established as an alternative to initiating chronic topical medication. International expansion of MIGS into Asia Pacific and Latin America represents a geographic growth opportunity as glaucoma specialist training in MIGS technique and reimbursement framework development for trabecular stent procedures matures in markets where MIGS adoption currently lags North America and Europe.
5. Top Companies in the Glaucoma Device Market
The following organisations hold leading positions in the Glaucoma Device Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Glaukos
- Alcon (iStent)
- Ivantis (Hydrus)
- New World Medical (Ahmed)
- Lumenis
- Iridex
- Ellex Medical
- QLT
- Sight Sciences
- Transcend Medical
6. Market Segmentation
The Glaucoma Device Market is analysed across 5 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Device Type | Trabecular Bypass MIGS Subconjunctival MIGS Suprachoroidal MIGS Tube Shunt Laser Platform |
| By Procedure | Standalone Glaucoma Surgery Combined Cataract-Glaucoma Surgery |
| By Glaucoma Type | Open-Angle Angle-Closure Secondary Normal-Tension |
| By End User | Glaucoma Specialty Programs Comprehensive Eye Care Practices |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Glaucoma Device Market trajectory over the forecast period:
MIGS Trabecular Bypass Stents Are Transforming Mild-to-Moderate Glaucoma Management as a Cataract Surgery Add-On.Trabecular bypass stents implanted through the anterior chamber angle reduce outflow resistance at the trabecular meshwork without requiring conjunctival manipulation, enabling glaucoma pressure reduction through the same small phacoemulsification incision used for cataract extraction. Published randomized trial data document meaningful additional intraocular pressure reduction and medication elimination in cataract patients receiving concurrent trabecular stent implantation compared to cataract surgery alone. The minimal-risk profile and absence of conjunctival scarring have made trabecular MIGS devices the fastest-adopted glaucoma surgical intervention category in contemporary ophthalmic surgery.
Subconjunctival Filtration MIGS Devices Are Extending Bleb-Based Filtration to Patients Previously Referred for Trabeculectomy.MIGS devices creating ab-interno subconjunctival filtration pathways establish conjunctival drainage with lower tissue manipulation than conventional trabeculectomy, extending bleb-based filtration to mild-to-moderate glaucoma patients who would previously require medical therapy escalation before surgical referral. Standalone implantation outside of cataract surgery provides pressure reduction in phakic and pseudophakic eyes, expanding MIGS application beyond the combined cataract-glaucoma procedure setting. Post-market surveillance data from commercial programs have characterized the bleb morphology, postoperative management requirements, and pressure outcomes of subconjunctival MIGS at practices with varied experience levels.
Selective Laser Trabeculoplasty With Short-Pulse Technology Is Offering a Repeatable Non-Incisional Pressure-Lowering Intervention.Selective laser trabeculoplasty applies low-energy nanosecond pulses to trabecular pigment cells, stimulating biological trabecular outflow enhancement through a mechanism that does not create thermal coagulation of adjacent tissue, allowing the procedure to be safely repeated when primary pressure reduction diminishes. The LiGHT randomized trial demonstrated that selective laser trabeculoplasty as initial glaucoma therapy produced non-inferior intraocular pressure control compared to topical medication initiation over 36 months, supporting its use as a first-line treatment alternative to drops. Short-pulse laser platforms delivering selective trabeculoplasty with nanosecond pulse duration extend the selectivity advantage of conventional selective laser trabeculoplasty.
For related market intelligence, see the Glaucoma Drug Market.
8. Segmental Analysis
By device type, the Trabecular Bypass MIGS segment dominated the Glaucoma Device Market in 2025, representing the majority of glaucoma device revenue in North America and Europe as concurrent cataract-glaucoma stent procedures became the predominant MIGS application, supported by reimbursement coverage, growing surgeon training penetration, and multiple competitive stent platforms with published randomized clinical trial data. The Subconjunctival Filtration MIGS segment is the fastest-growing device category, advancing as standalone subconjunctival drainage implants gain adoption at glaucoma specialty programs as a less invasive alternative to conventional trabeculectomy in mild-to-moderate open-angle glaucoma patients, reducing the surgical morbidity threshold for incisional glaucoma intervention.
By procedure, Combined Cataract-Glaucoma Surgery leads overall Glaucoma Device Market revenue as the most common MIGS application, while Standalone Glaucoma Device Procedures are registering the highest growth rate as subconjunctival and suprachoroidal MIGS expand the interventional glaucoma spectrum beyond the concurrent cataract surgery indication.
9. Regional Analysis
Regional demand patterns across the Glaucoma Device Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Glaucoma Device Market in 2025, accounting for approximately 48% of global revenue, driven by the rapid adoption of MIGS trabecular bypass stents at high-volume cataract surgery programs following CMS reimbursement for concurrent glaucoma stent implantation, the established glaucoma specialist and comprehensive ophthalmologist training in MIGS technique, and FDA clearance of multiple trabecular bypass, subconjunctival filtration, and suprachoroidal MIGS platforms creating a commercially diverse device selection. Moreover, the LiGHT trial evidence supporting selective laser trabeculoplasty as first-line therapy has driven laser system investment at US glaucoma practices offering office-based pressure-lowering as an alternative to initiating topical medication. In addition, the concentration of MIGS clinical trial enrollment at US academic glaucoma programs has sustained North America as the primary validation and early adoption market for successive MIGS device generations. The established reimbursement framework, surgeon training penetration, and multi-platform device availability sustain North American dominance in the Glaucoma Device Market through the forecast period.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Glaucoma Device Market through 2034, advancing at approximately 18.5%, driven by the large and growing glaucoma patient population in aging societies across Japan, China, South Korea, and Australia, increasing awareness of MIGS as a less invasive glaucoma surgical option among ophthalmologists trained in cataract surgery, and growing government and private insurance coverage for glaucoma device procedures in major Asia Pacific healthcare systems. The region benefits from high cataract surgery volumes in China, India, and Japan that create large populations of concurrent cataract-glaucoma patients appropriate for combined procedures, providing a substantial immediate adoption opportunity as MIGS regulatory approvals and surgeon training programs expand across the region. Moreover, selective laser trabeculoplasty adoption at hospital-based glaucoma clinics in Asia Pacific is accelerating as domestically priced laser systems become available and the LiGHT trial's first-line therapy data gain recognition in Asian ophthalmology guideline updates. The combination of large glaucoma burden, growing MIGS regulatory access, and cataract surgery volume synergies positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Glaucoma Device Market was valued at USD 4.51 Bn in 2025 and is projected to reach USD 15.61 Bn by 2034, growing at a CAGR of 14.8% over the 2026–2034 forecast period.
The Glaucoma Device Market is projected to grow at a CAGR of 14.8% from 2026 to 2034.
North America dominated the Glaucoma Device Market in 2025, accounting for approximately 48% of global revenue, driven by the rapid adoption of MIGS trabecular bypass stents at high-volume cataract surgery programs following CMS reimbursement for concurrent glaucoma stent implantation, the established glaucoma specialist and comprehensive ophthalmologist training in MIGS technique, and FDA clearance of multiple trabecular bypass, subconjunctival filtration, and suprachoroidal MIGS platforms creating a commercially diverse device selection.
The leading companies in the Glaucoma Device Market include Glaukos, Alcon (iStent), Ivantis (Hydrus), New World Medical (Ahmed), Lumenis, Iridex, Ellex Medical, QLT, Sight Sciences, Transcend Medical.
Migs trabecular bypass stents are transforming mild-to-moderate glaucoma management as a cataract surgery add-on.
By device type, the Trabecular Bypass MIGS segment dominated the Glaucoma Device Market in 2025, representing the majority of glaucoma device revenue in North America and Europe as concurrent cataract-glaucoma stent procedures became the predominant MIGS application, supported by reimbursement coverage, growing surgeon training penetration, and multiple competitive stent platforms with published randomized clinical trial data.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.